London, UK: Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug-plus-software precision therapy products that deliver personalized dose optimization to treat the individual, not just the disease, has joined the NVIDIA Inception program. Led by world-leading Artificial Intelligence Computing company, NVIDIA, the accelerator program is designed to nurture startups and early-stage companies revolutionizing industries with technological advancements.
Unlike traditional accelerators, NVIDIA’s Inception program supports all stages of a start-up’s life cycle, providing access to the latest tools, expertise, and a network of venture capitalist investors, to accelerate solution development and business growth.
NVIDIA Inception works closely with companies across product development, prototyping, and deployment. Every member gets a custom set of ongoing benefits, including engineering guidance, preferred pricing on NVIDIA hardware and software, and leading technical training through expanded access to its Deep Learning Institute, Developer Forums, and exclusive Inception events. The program also offers increased exposure to investor contacts and key industry leaders through Inception Capital Connect, providing companies the fundamental resources for growth.
Closed Loop Medicine joins NVIDIA Inception at a pivotal stage as the Company prepares for breakthrough milestones in the progression and commercialization of its product pipeline. The announcement builds on a year of transformational growth, including publication of clinical trial data validating use of the Company’s proprietary technology for personalized treatment of hypertension, followed by several partnerships with leading pharmaceutical companies to apply the technology more broadly. The program will support the Company as it drives development of its expanding portfolio of ML-driven predictive dosing products and entry into broader therapeutic areas with high unmet clinical need.
Dr. Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, said: “This is yet further industry validation for the Company’s potential to transform healthcare and improve patient outcomes – recognized by a world-leading company. Leveraging the resources at NVIDIA Inception will help support our mission to deliver precision care to all.” He continues, “Personalized healthcare has been limited to a privileged few, resulting in missed opportunities to provide early, effective, and equitable treatment to everyone. We are looking forward to maximizing the tools and network from the program to further develop our product portfolio and deliver personalized dose optimization for all.”
